Differences

This shows you the differences between two versions of the page.

--- home:protocol:olmesartan [02.25.2019] – [Kidney disease] sallieq
+++ home:protocol:olmesartan [03.22.2020] – [Science behind olmesartan (Benicar)] sallieq
@@ Line 1: / Line 1: @@
 ====== Science behind olmesartan (Benicar)     ======
+<relatedarticle> [[home:food:aim_health:aging|Health maintenance and Olmesartan]] </article>
 Patients on the [[home:protocol|Marshall Protocol]] (MP) take olmesartan (Benicar), a drug whose actions are well known, [[home:mp:olmesartan:dosing|every six hours]].  In general, olmesartan tends to be prescribed for its antihypertensive properties due to the fact that is an angiotensin receptor blocker. A growing body of research supports the use of olmesartan as a part of a curative therapy for chronic disease.
@@ Line 123: / Line 126: @@
   * inhibit liver fibrosis and aid liver healing(({{pubmed>long:12871826}}))
   * reduce insulin resistance in rats(({{pubmed>long:15127887}}))
-  * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed>long:23775504}}))
+  * 6 mg/kg olmesartan reduces the inflammatory process and periodontal bone loss in rats(({{pubmed>long:23775504}}))
   * protect the mitochondria from age-associated damage from oxidation(({{pubmed>long:12709417}}))
   * play a protective role against proliferative diabetic retinopathy (({{pubmed>long:17560613}}))
@@ Line 200: / Line 204: @@
-{{tag>olmesartan Science}}
+{{tag>olmesartan Science research}}
 ===== Notes and comments =====

home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1